Analyst firms · Needham · HAE
Needham HAE price target and rating history
Haemonetics Corporation (HAE) · Health Care
Needham rates Haemonetics Corporation (HAE) Hold with a $112 price target, as of its latest action on Dec 15, 2025. It has published 3 rating actions on HAE since January 2022, including 1 upgrade and 2 downgrades. Across 3 firms with a HAE price target in the last 12 months, the median target is $89.
- Current rating
- Hold
- Price target
- $112
- Median target, all firms
- $89
- Actions on HAE
- 3
Every Needham rating on HAE
- Dec 15, 2025DowngradeNeedham downgrades to Hold from Buy
- Jun 12, 2024
- Jan 27, 2022DowngradeNeedham downgrades to Hold from Buy
How other firms rate HAE
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Citigroup | Buy | $123 | Sep 17, 2026 |
| BofA Securities | Buy | $80 | May 22, 2026 |
| Barrington Research | Outperform | $89 | May 12, 2026 |
| Needham | Hold | Dec 15, 2025 |
Questions about Needham and HAE
- What is Needham's price target for HAE?
- Needham's latest stated price target for Haemonetics Corporation (HAE) is $112, from its action on Jun 12, 2024.
- What is Needham's rating on HAE?
- Needham rates HAE Hold, a neutral rating, as of Dec 15, 2025.
- When did Needham last change its view on HAE?
- On Dec 15, 2025, Needham downgrades to Hold from Buy.
- How does Needham's HAE target compare with other analysts?
- Across 3 firms with a HAE price target in the last 12 months, the median target is $89.
More HAE rating histories
All Needham ratingsHAE news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.